食管癌同步放化疗与单纯超分割放疗的疗效对比观察

目的比较化疗同时超分割放疗与单纯超分割放疗对中上段食管癌的近期疗效和长期生存率.方法 158 例中上段食管癌患者随机分为两组,75例列入放化疗同步组, 3 例列入单放组, 化疗方案:DDP 0 g/m2 v tt 1～d5,5-FU 00 g/m2 静滴d1～d5,连续静滴6～8 ,化疗并同时放疗,两组超分割放疗方法相同:1.3 y/次,2次/日.结果同步放化疗组近期有效率为84.0％,1、3、5年生存率分别为70.7％、40.0％和24.0％;单放组的近期有效率为67.5％,1、3、年生存率分别为51.8％、21.7％和10.8％.经χ2检验,差异有显著意义,两组毒副作用均可以耐受.结论以DDP及5-FU 化疗同步超分割放疗可以提高中上段食管癌的近期有效率及长期生存率,毒副反应所有患者均能耐受.

Synchronic radiotherapy-chemotherapy compared with radiotherapy alone in patients with upper and middle esophageal cancer

Objective To compare the short term effectivity, and survival rates of hyperfractionated radiotherapy plus chemotherapy concurrutly with hyperfractionated radiotherapy alone in patients with upper and middle esophageal cancer. Metheds:One hundred and fifty eight patients with upper and middle esophageal cancer were randomized into two groups where 75 treated by chemoradiotherapy(CRT) and 83 by radiotherapy(RT) alone. The chemotherapy included cispatin 20 mg/m 2 on d1 d5 infusion, 5 fluorouracil 500 mg/m 2 on d1 d5 by continuous infusion for 6 8 hours.Hyperfractionated radiotherapy were similar in the two groups:1.3 Gy/f,twice a day.Results 1 , 3 , 5 year suvival rates were 70.7%,40.0% and 24.0% for CRT and 51.8%,21.7%,10.8% for RT, respectively. The difference is statistically significant. The toxic and side effects are tolerable in the two groups. Conclusion Concurrut chemotherapy with 5 fluorouracil, cisplatin combimed hyperfractionated radiotherapy may improve the outcome of esophageal cancer, with the toxic and side effects being tolerated by all patients.